Literature DB >> 29853482

Survival and Disease-Free Survival by Breast Density and Phenotype in Interval Breast Cancers.

Maria Sala1,2, Laia Domingo3,2, Javier Louro3,2, Isabel Torá-Rocamora3, Marisa Baré2,4,5, Joana Ferrer6, Maria Carmen Carmona-Garcia7,8,9, Teresa Barata10, Marta Román3,2, Francesc Macià3, Xavier Castells.   

Abstract

Background: We aimed to evaluate survival and disease-free survival in different subtypes of interval cancers by breast density, taking into account clinical and biological characteristics.
Methods: We included 374 invasive breast tumors (195 screen-detected cancers; 179 interval cancers, classified into true interval, false-negatives, occult tumors and minimal-sign cancers) diagnosed in women ages 50-69 years undergoing biennial screening from 2000-2009, followed up to 2014. Breast density was categorized into non-dense (<25% dense tissue) and mixed dense breasts (≥25%). Survival curves were generated by the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression models were computed to estimate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) for death and recurrences by comparing women with interval and true interval cancers versus women with screen-detected cancers, controlling for tumor and patient characteristics. All analyses were stratified by breast density.
Results: Interval cancers were detected in younger women, at more advanced stages, in denser breasts and showed a higher proportion of triple-negative cancers, especially among true interval cancers. Women with interval cancer and non-dense breasts had an aHR for death of 3.40 (95% CI, 0.92-12.62). Women with true interval cancers detected in non-dense breasts had the highest adjusted risk of death (aHR, 6.55; 95% CI, 1.37-31.39).Conclusions: Women with true interval cancer in non-dense breasts had a higher risk of death than women with screen-detected cancers.Impact: These results support the advisability of routinely collecting information on breast density, both for further tailoring of screening strategies and as a prognostic factor for diagnosed breast cancers. Cancer Epidemiol Biomarkers Prev; 27(8); 908-16. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29853482     DOI: 10.1158/1055-9965.EPI-17-0995

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

Review 1.  Redefining the sensitivity of screening mammography: A review.

Authors:  Alan B Hollingsworth
Journal:  Am J Surg       Date:  2019-02-02       Impact factor: 2.565

2.  Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.

Authors:  Veronica L Irvin; Zhenzhen Zhang; Michael S Simon; Rowan T Chlebowski; Shiuh-Wen Luoh; Aladdin H Shadyab; Jessica L Krok-Schoen; Fred K Tabung; Lihong Qi; Marcia L Stefanick; Pepper Schedin; Sonali Jindal
Journal:  JAMA Netw Open       Date:  2020-06-01

3.  Poor Biological Factors and Prognosis of Interval Breast Cancers: Long-Term Results of Bahçeşehir (Istanbul) Breast Cancer Screening Project in Turkey.

Authors:  Neslihan Cabioğlu; Sibel Özkan Gürdal; Arda Kayhan; Nilüfer Özaydın; Cennet Şahin; Ömür Can; Beyza Özçınar; Gönül Aykuter; Gülçin Vatandaş; Erkin Aribal; Vahit Özmen
Journal:  JCO Glob Oncol       Date:  2020-07

4.  Radiological audit of interval breast cancers: Estimation of tumour growth rates.

Authors:  Emma G MacInnes; Stephen W Duffy; Julie A Simpson; Matthew G Wallis; Anne E Turnbull; Louise S Wilkinson; Keshthra Satchithananda; Rumana Rahim; David Dodwell; Brian V Hogan; Oleg Blyuss; Nisha Sharma
Journal:  Breast       Date:  2020-04-01       Impact factor: 4.380

5.  Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening.

Authors:  Irene Zarcos-Pedrinaci; Maximino Redondo; Javier Louro; Francisco Rivas-Ruiz; Teresa Téllez; Diego Pérez; Francisco Medina Cano; Kenza Machan; Laia Domingo; Maria Mar Vernet; Maria Padilla-Ruiz; Xavier Castells; Antonio Rueda; María Sala
Journal:  Cancer Med       Date:  2019-09-24       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.